China Healthcare Sector:Comment on 2016medicinehealth product import and export figures

类别:行业研究 机构:瑞银证券有限责任公司 研究员:Bing Zhao,Fengzhan Zhang,Na Lin 日期:2017-03-08

Medicine/health product imports and exports rose 0.73% YoY

    According to the China Chamber of Commerce for Import & Export of Medicines andHealth Products, China's medicine/health product imports and exports stood atUS$103.4bn in 2016, up 0.73% YoY; exports fell 1.82% YoY to US$55.4bn, whileimports rose 3.83% YoY to US$48bn. Excluding the effects of the exchange rate,imports and exports jumped 7.12% in RMB terms, with exports/imports up4.41%/10.42%. Overall imports and exports showed steady growth.

    TCM raw materials/decoction pieces suffered biggest fall

    Imports and exports of TCM raw materials/decoction pieces were US$1.164bn, down4.85% YoY; imports were US$139m (-15.84% YoY) and exports were US$1.025bn(-3.13% YoY). TCM raw materials/decoction pieces suffered the biggest fall among allmedicines. We attribute their sluggish imports/exports mainly to the following: 1) somecompanies' TCM raw materials are substandard and industry standardization has justbegun; and 2) due to the uniqueness of TCM, barriers to entry are high in places suchas EU.

    Medical equipment export mix improving

    Medical equipment imports and exports grew 1.10% YoY to US$38.9bn in 2016;imports/exports were up/down 6.28%/3.14% YoY, at US$18.4bn/20.5bn. Looking atthe mix of medical equipment imports and exports, the proportion of traditionalmedical dressings is falling, while that of higher-value hospital diagnosis/treatment andhealthcare/rehabilitation equipment is rising.

    Optimistic about preparation exporters

    Preparations have a higher value compared with APIs (low gross and net margins).

    More and more companies are shifting from API intermediate to preparation exportsand preparation-exporting countries are shifting to developed nations. We areoptimistic about preparation exporters with an improved export mix and companiesexpanding distribution channels overseas, such as Huahai Pharmaceutical.

数据推荐

投资评级

更多>>
股票名称最新评级目标价研报

盈利预测

评级选股>>
股票名称11年EPS12年EPS研报
新城控股 0 0 研报
光大嘉宝 0.60 0 研报
世联行 0.84 0.62 研报
大悦城 0.30 0.27 研报
蓝光发展 0.24 0 研报
荣盛发展 0.75 1.04 研报
绿地控股 0.55 0.30 研报
金融街 0.64 0.72 研报
新湖中宝 0.38 0.32 研报
金地集团 0.67 0.71 研报
滨江集团 0.80 0.93 研报

股票关注度

更多>>
股票名称关注度平均评级最新评级
海康威视 6 持有 买入
华夏幸福 4 买入 买入
恒逸石化 4 买入 买入
南极电商 4 买入 买入
洽洽食品 4 持有 买入
贵州茅台 3 持有 买入
普洛药业 3 买入 买入
旗滨集团 3 买入 买入
喜临门 3 买入 买入
中南建设 3 买入 买入
比音勒芬 2 买入 持有
吉比特 2 持有 买入
完美世界 2 持有 买入
万科A 2 买入 买入
大悦城 2 买入 买入
美的集团 2 买入 买入
新经典 2 持有 中性

行业关注度

更多>>
行业名称关注度关注股票数买入评级数